宏基因组测序用于输血传播病原体筛查的研究现状与展望  

Research status and prospect of metagenomic sequencing for the screening of blood transfusion transmitted pathogens

作　　者：单振刚[1] 王敏[1] 许茹[1] 廖峭[1] 黄杰庭[1] 钟惠珊 付涌水[1] 戎霞[1] Shan Zhengang;Wang Min;Xu Ru;Liao Qiao;Huang Jieting;Zhong Huishan;Fu Yongshui;Rong Xia(Institute of Clinical Blood Transfusion,Guangzhou Blood Center,Guangzhou 510095,China)

机构地区：[1]广州血液中心临床输血研究所,广州510095

出　　处：《中华实验和临床病毒学杂志》2023年第4期449-454,共6页Chinese Journal of Experimental and Clinical Virology

基　　金：广州市科技计划(202002030192);广东省医学科学技术研究基金(B2022150)。

摘　　要：血液筛查对于保障血液安全至关重要。传统方法在检测未知病原体方面效果不佳,以高通量测序为主要手段的血液宏基因组分析不局限于特定微生物而是以样品中的所有微生物(总基因组)为研究对象,具有传统方法不能比拟的优势。随着测序技术的日益成熟,检测成本的逐渐降低,宏基因组测序技术的应用也越来越广泛。本文对宏基因组学的概念、研究过程、宏基因组测序技术在输血传播病原体筛查领域的应用现状及未来展望进行综述。Blood screening is essential for blood safety.Traditional methods are not very effective in unknown pathogen testing.The blood metagenomic analysis with high-throughput sequencing as the main method is not limited to a particular microbe but detects all microbes in the sample(total genome),which has advantages that traditional methods cannot compare with.With the increasingly maturation of technology and the gradual reduction of cost,metagenomic sequencing has been applied more and more widely.In this paper,the concept and research procedures of metagenomics,the current status and future prospect of metagenomics sequencing technology in the field of blood screening are reviewed.

关 键 词：宏基因组 高通量测序 献血者 血液筛查 

分 类 号：R457.1[医药卫生—治疗学]